Harmony Biosciences Holdings set terms for its initial public offering on Tuesday, with plans to offer 4.65 million shares priced at $20 to $23 each. The company has applied to list on Nasdaq, under the ticker ‘HRMY.’ Goldman Sachs, Jefferies and Piper Sandler are underwriting the deal. Proceeds will be used to fund clinical development and for general working purposes, including a potential milestone payment to Bioprojet. “We are a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs,” the company says in its prospectus. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.